Cancer Research and Treatment

Original Articles

Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study: Danbee Kang, Juhee Cho, Im Ryung Kim, Mi Kyung Kim, Won Seog Kim, Seok Jin Kim; Cancer Res Treat. 2018;50(4):1051-1063. Published online November 9, 2017; DOI: https://doi.org/10.4143/crt.2017.207

Abstract PDF Supplementary Material PubReader ePub

Purpose
We evaluated health-related quality of life (HRQOL) in long-term survivors of indolent and aggressive non-Hodgkin lymphoma (NHL).
Materials and Methods
TheHRQOLwas assessed by the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (EORTC QLQ-C30) at diagnosis in NHL patients between 2008 and 2011, and follow-up evaluation was conducted from June 2014 to February 2015 using EORTC QLQ-C30 and the quality of life in cancer survivors (QOL-CS) questionnaire. We used linear mixed models to compare changes in HRQOL between indolent and aggressive NHL over time.
Results
The HRQOL of long-term survivors with aggressive NHL improved to the similar level of indolent NHL during the follow-up survey. However, survivors of NHL were found to fear the probability of relapse and second malignancy, and the degree of fear was not different between survivors with aggressive stage I/II or III/IV NHL (p > 0.05). Furthermore, a half of survivors reported impaired sense of psychosocial well-being regardless of aggressiveness and stage during follow-up survey. More than 65% of survivors thought they did not receive sufficient support from others, and patients who had financial difficulties at diagnosis were more frequently associated with suffering from insufficient support. Impaired physical and cognitive functioning at diagnosis was significantly associated with lack of life purpose in long-term survivors.
Conclusion
The HRQOL of aggressive NHL survivors improved to a similar level to that of indolent NHL. However, the majority of survivors still had fear of relapse, and psychosocial well-being remained unmet needs.

Citations

Citations to this article as recorded by

Attenuated adiponectin, omentin, increased interleukin-6 and tumor necrosis factor-alpha levels with altered cognition and depression in non-Hodgkin lymphoma patients: A case-control study
Meghavi Kathpalia, Pinki Mishra, Afsha Majid, Mohd. Ashif Khan, Anurag Sharma, Dinesh Bhurani, Nidhi
Journal of Neuroimmunology.2024; 392: 578372. CrossRef
Quality of life and late therapy effects in pediatric non‐Hodgkin lymphoma survivors: Insights from a single‐institution study
Azza Ayad, Reham Khedr, Asmaa Hamoda, Nahla Elnabarawy, Elhamy Rifky, Tamer Diab, Eman El Desouky, Leslie Lehmann, Alaa Elhaddad
Pediatric Blood & Cancer.2024;[Epub] CrossRef
Willingness to pay per quality-adjusted life year of Non-Hodgkin Lymphoma patients in Vietnam
Phan Gia Huy, Pham Xuan Dung, Dang The Thap, Nguyen Tran Nhu Y
Tạp Chí Khoa học Trường Đại học Quốc tế Hồng Bàng.2024; : 11. CrossRef
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study
Sohee Park, Ju Hwan Kim, Songhee Kim, Jisu Kang, Seoyoung Moon, Seok Jin Kim, Ju-Young Shin
Blood Cancer Journal.2023;[Epub] CrossRef
Factors associated with long-term functional and psychosocial outcomes in patients with non-Hodgkin lymphoma
Bhasker Amatya, Michael Dickinson , Fary Khan
Journal of Rehabilitation Medicine.2023; 55: jrm004816. CrossRef
Experiences of and preferences for self-management among low grade non-Hodgkin's lymphoma survivors: A qualitative interview study
Nickola D. Pallin, Mairead O'Connor, Alannah Gannon, John Browne, Mary R. Cahill, Derville O'Shea
European Journal of Oncology Nursing.2023; 66: 102378. CrossRef
Factors Affecting Health-Related Quality of Life among Survivors of Non-Hodgkin Lymphoma: A Population-Based Study
Stephane Kroudia Wasse, Morgane Mounier, Emerline Assogba, Cédric Rossi, Johan Adnet, Sophie Gauthier, Stephanie Girard, Kueshivi Midodji Atsou, Tienhan Sandrine Dabakuyo-Yonli, Marc Maynadie
Cancers.2023; 15(15): 3885. CrossRef
Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study
Leo I. Gordon, Fei Fei Liu, Julia Braverman, Daanish Hoda, Nilanjan Ghosh, Mehdi Hamadani, Gerhard C. Hildebrandt, Lily Peng, Shien Guo, Ling Shi, Alison Sehgal
Haematologica.2023; 109(3): 857. CrossRef
Quality of life and fear of cancer recurrence in patients and survivors of non-Hodgkin lymphoma
Susan Ellis, Rhonda F. Brown, Einar B. Thorsteinsson, Kenneth I. Pakenham, Colin Perrott
Psychology, Health & Medicine.2022; 27(8): 1649. CrossRef
Pre‐treatment health‐related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA‐BERIT) experience
Åsa Lindberg, Christian Winther Eskelund, Alexandra Albertsson‐Lindblad, Arne Kolstad, Anna Laurell, Riikka Räty, Kirsten Grønbæk, Christian Hartmann Geisler, Mats Jerkeman
Hematological Oncology.2022; 40(1): 23. CrossRef
Treatment Outcomes and Its Associated Factors Among Adult Patients with Selected Solid Malignancies at Kenyatta National Hospital: A Hospital-Based Prospective Cohort Study
Amsalu Degu, Ermias Mergia Terefe, Eliab Seroney Some, Gobezie T Tegegne
Cancer Management and Research.2022; Volume 14: 1525. CrossRef
Living with or beyond lymphoma: A rapid review of the unmet needs of lymphoma survivors
Vanessa Boland, Amanda Drury, Greg Sheaf, Anne‐Marie Brady
Psycho-Oncology.2022; 31(7): 1076. CrossRef
The forgotten survivor: A comprehensive review on Non‐Hodgkin lymphoma survivorship
Mohamad S. Alabdaljabar, Urshila Durani, Carrie A. Thompson, Louis S. Constine, Shahrukh K. Hashmi
American Journal of Hematology.2022; 97(12): 1627. CrossRef
Unmet Needs and Quality of Life of Colorectal Cancer Survivors Immediately after Treatment Ends and 5 Years
Hyedan Kim, Eunsook Wi, Mi Hwa Jang, Sung Hee Jo, Hye Kyung Kim
Asian Oncology Nursing.2022; 22(3): 145. CrossRef
Trajectories of symptom severity predicts quality of life change in newly diagnosis lymphoma survivors: An initial study
Chih‐Jung Wu, Yu‐Chi Chen, Li‐Yuan Bai, Tzeon‐Jye Chiou, Kuan‐Chia Lin, Ya‐Jung Wang
European Journal of Cancer Care.2022;[Epub] CrossRef
Exploring health-related quality of life among non-Hodgkin’s lymphoma survivors after completion of primary treatment: a cross-sectional study in Thailand
Pichitra Lekdamrongkul, Kanaungnit Pongthavornkamol, Alex Molassiotis, Aurawamon Sriyuktasuth, Noppadol Siritanaratkul, Natkamol Chansatitporn
Supportive Care in Cancer.2021; 29(11): 6511. CrossRef
Experiences of patients with lung cancer receiving concurrent chemo-radiotherapy
Choi Eunsook, Park Sunhee
Clinical Journal of Nursing Care and Practice.2021; 5(1): 015. CrossRef
Coping strategies among patients with malignant lymphoma– a qualitative study from the perspectives of Swedish patients
Stinne Glasdam, Charlotta Bjerström, Cecilia Engberg de Carvalho
European Journal of Oncology Nursing.2020; 44: 101693. CrossRef
Impact of fear of cancer recurrence on survival among lymphoma patients
Seok Jin Kim, Danbee Kang, Im Ryung Kim, Sang Eun Yoon, Won Seog Kim, Phyllis N. Butow, Eliseo Guallar, Juhee Cho
Psycho-Oncology.2020; 29(2): 364. CrossRef
Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma
Andrew Davies, Peter Trask, Judit Demeter, Axel Florschütz, Mathias Hänel, Tomohiro Kinoshita, Ruth Pettengell, Hang Quach, Stephen Robinson, Shalal Sadullah, Juan-Manuel Sancho, Miklos Udvardy, Mathias Witzens-Harig, Andrea Knapp, Wenxin Liu
Annals of Hematology.2020; 99(12): 2837. CrossRef
Quality of Life and Impact of Cancer: Differences in Rural and Nonrural Non‐Hodgkin's Lymphoma Survivors
Devon Noonan, Matthew LeBlanc, Cherie Conley, Habtamu Benecha, Ashley Leak‐Bryant, Kellen Peter, Sheryl Zimmerman, Deborah Mayer, Sophia Smith
The Journal of Rural Health.2020; 36(4): 536. CrossRef
Semen quality in non-Hodgkin lymphoma survivors: a monocentric retrospective study
Francesco Pallotti, Marianna Pelloni, Fabiana Faja, Silvia Di Chiano, Alice Di Rocco, Andrea Lenzi, Francesco Lombardo, Donatella Paoli
Human Reproduction.2020;[Epub] CrossRef
Prognostic Value of Post-diagnosis Health-Related Quality of Life for Overall Survival in Breast Cancer: Findings from a 10-Year Prospective Cohort in Korea
Tran Thi Xuan Mai, Jin Hyuk Choi, Myung Kyung Lee, Yoon Jung Chang, So-Youn Jung, Hyunsoon Cho, Eun Sook Lee
Cancer Research and Treatment.2019; 51(4): 1600. CrossRef

17,438 View
425 Download
21 Web of Science
23 Crossref

The Impact of High-Risk HPV Genotypes Other Than HPV 16/18 on the Natural Course of Abnormal Cervical Cytology: A Korean HPV Cohort Study: Kyeong A So, Mi Jung Kim, Ki-Heon Lee, In-Ho Lee, Mi Kyung Kim, Yoo Kyung Lee, Chang-Sun Hwang, Mi Seon Jeong, Mee-Kyung Kee, Chun Kang, Chi Heum Cho, Seok Mo Kim, Sung Ran Hong, Ki Tae Kim, Won-Chul Lee, Jong Sup Park, Tae Jin Kim; Cancer Res Treat. 2016;48(4):1313-1320. Published online March 9, 2016; DOI: https://doi.org/10.4143/crt.2016.013

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to evaluate the impact of high-risk human papillomaviruses (HPVs) other than HPV 16/18 on the natural course of atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL).
Materials and Methods
The study population was derived from the Korean HPV cohort (2010-2014). Women aged 20 to 60 who satisfied the criteria of having both HPV infection and abnormal cervical cytology of either ASC-US or LSIL were recruited from five institutions nationwide. Enrolled patients underwent cervical cytology and HPV DNA testing every 6 months.
Results
A total of 1,158 patients were enrolled. The 10 most common HPV types were HPV 16 (12.3%), 58 (10.0%), 56 (8.8%), 53 (8.4%), 52 (7.7%), 39 (6.2%), 18 (6.0%), 51 (5.7%), 68 (5.1%), and 66 (4.6%). Among these patients, 636 women were positive for high-risk HPVs other than HPV 16 or 18, and 429 women were followed for more than 6 months. Cytology evaluations showed progression in 15.3% of women, no change in 22.6%, and regression in 62.1% of women at 12 months. In cases of HPV 58 single infection, a more highly significant progression rate, compared to other high-risk types, was observed at 6 months (relative risk [RR], 3.3; 95% confidence interval [CI], 2.04 to 5.30; p < 0.001) and 12 months (RR, 5.03; 95% CI, 2.56 to 9.91; p < 0.001).
Conclusion
HPV genotypes numbered in the 50s were frequent in Korean women with ASC-US and LSIL. HPV 58 was the second most common type, with a high progression rate of cervical cytology.

Citations

Citations to this article as recorded by

Women 50 Years and Older With Negative Pap Test and Positive Human Papillomavirus Test for Genotypes Other Than 16 and 18—Follow-up Outcomes
Farah S. Baban, Michael R. Henry, Margaret E. Long, Meredith A. VandeHaar, Grant M. Spears, Sarah M. Jenkins, Diva R. Salomao
Journal of Lower Genital Tract Disease.2024; 28(1): 43. CrossRef
Cervical intraepithelial neoplasia in non-16/18 high-risk human papilloma virus positive/cytology negative women: An alternative approach in poor resource areas
Fariba Yarandi, Elham Shirali, Elham Feizabad, Sara Ramhormoziyan, Soheila Sarmadi, Maryam SadrAmeli, Elham Arshadi
Taiwanese Journal of Obstetrics and Gynecology.2023; 62(2): 299. CrossRef
Molecular markers predicting the progression and prognosis of human papillomavirus-induced cervical lesions to cervical cancer
Fatema Alzahraa Samy Amin, Zeba Un Naher, P. Shaik Syed Ali
Journal of Cancer Research and Clinical Oncology.2023; 149(10): 8077. CrossRef
Herpes Simplex Virus, Human Papillomavirus, and Cervical Cancer: Overview, Relationship, and Treatment Implications
Daniel Sausen, Oren Shechter, Elisa Gallo, Harel Dahari, Ronen Borenstein
Cancers.2023; 15(14): 3692. CrossRef
Association strength of E6 to E6AP/p53 complex correlates with HPV‐mediated oncogenesis risk
Matheus Vitor Ferreira Ferraz, Isabelle Freire Tabosa Viana, Danilo Fernandes Coêlho, Carlos Henrique Bezerra da Cruz, Maíra de Arruda Lima, Madson Allan de Luna Aragão, Roberto Dias Lins
Biopolymers.2022;[Epub] CrossRef
Diagnostic performance of immediate colposcopy among women with high‐risk human papillomavirus (HPV) other than HPV 16/18 and normal cytology
Serdar Aydın, Hande Nur Öncü, Dilek Sema Arıcı
Journal of Obstetrics and Gynaecology Research.2021; 47(2): 720. CrossRef
Mixed and nonvaccine high risk HPV types are associated with higher mortality in Black women with cervical cancer
Rachelle P. Mendoza, Tahmineh Haidary, Elmer Gabutan, Ying Yin Zhou, Zaheer Bukhari, Courtney Connelly, Wen-Ching Lee, Yi-Chun Lee, Raj Wadgaonkar, Raag Agrawal, M. A. Haseeb, Raavi Gupta
Scientific Reports.2021;[Epub] CrossRef
Distribution of HPV genotypes among women with abnormal cytology results in Alberta, Canada
Sabrina S Plitt, Ryan Kichuk, Sheena Geier, Trenton Smith, Felicia Roy, Alberto Severini, Carmen L Charlton
Journal of the Association of Medical Microbiology and Infectious Disease Canada.2021; 6(2): 94. CrossRef
The Clinical Significance and Utility of HPV-DNA Testing in Korean Women with Atypical Glandular Cells in Cervical Pap Tests: An Analysis of 311 Cases at a Single Institution
Tae-Kyu Jang, Jeong-Yeol Park, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam
Cancer Investigation.2021; 39(10): 885. CrossRef
Enhanced disease progression due to persistent HPV-16/58 infections in Korean women: a systematic review and the Korea HPV cohort study
Jaehyun Seong, Sangmi Ryou, JeongGyu Lee, Myeongsu Yoo, Sooyoung Hur, Byeong-Sun Choi
Virology Journal.2021;[Epub] CrossRef
Risk of cervical lesions in high-risk HPV positive women with normal cytology: a retrospective single-center study in China
Zhiling Wang, Ting Liu, Yunjian Wang, Ying Gu, Hui Wang, Jingkang Liu, Baoxia Cui, Xingsheng Yang
Infectious Agents and Cancer.2020;[Epub] CrossRef
Co-infection between genotypes of the human papillomavirus and Chlamydia trachomatis in Mexican women
Marco A Escarcega-Tame, Marcela López-Hurtado, Marcos R Escobedo-Guerra, Elba Reyes-Maldonado, Graciela Castro-Escarpulli, Fernando M Guerra-Infante
International Journal of STD & AIDS.2020; 31(13): 1255. CrossRef
Artificial intelligence estimates the impact of human papillomavirus types in influencing the risk of cervical dysplasia recurrence: progress toward a more personalized approach
Giorgio Bogani, Antonino Ditto, Fabio Martinelli, Mauro Signorelli, Valentina Chiappa, Umberto Leone Roberti Maggiore, Francesca Taverna, Claudia Lombardo, Chiara Borghi, Cono Scaffa, Domenica Lorusso, Francesco Raspagliesi
European Journal of Cancer Prevention.2019; 28(2): 81. CrossRef
Human papillomavirus genotype-specific risk in cervical carcinogenesis
Kyeong A So, In Ho Lee, Ki Heon Lee, Sung Ran Hong, Young Jun Kim, Hyun Hee Seo, Tae Jin Kim
Journal of Gynecologic Oncology.2019;[Epub] CrossRef
Comparison of the PANArray HPV Genotyping Chip Test with the Cobas 4800 HPV and Hybrid Capture 2 Tests for Detection of HPV in ASCUS Women
Eun Young Ki, Yoon Kyung Lee, Ahwon Lee, Jong Sup Park
Yonsei Medical Journal.2018; 59(5): 662. CrossRef
Genetic variability in E6, E7 and L1 genes of Human Papillomavirus 62 and its prevalence in Mexico
Cristina Artaza-Irigaray, María Guadalupe Flores-Miramontes, Dominik Olszewski, María Teresa Magaña-Torres, María Guadalupe López-Cardona, Yelda Aurora Leal-Herrera, Patricia Piña-Sánchez, Luis Felipe Jave-Suárez, Adriana Aguilar-Lemarroy
Infectious Agents and Cancer.2017;[Epub] CrossRef

33,962 View
301 Download
16 Web of Science
16 Crossref

Association between Health Behaviors and a Family History of Cancer among Korean Women: Youngsun Ham, Hea Young Oh, Sang-Soo Seo, Mi Kyung Kim; Cancer Res Treat. 2016;48(2):806-814. Published online September 22, 2015; DOI: https://doi.org/10.4143/crt.2015.083

Abstract PDF PubReader ePub

Purpose
The aim of this study was to examine the health-related behaviors related to a family history of cancer (FHCA) among Korean women underwent cancer screening.
Materials and Methods
A total of 8,956 women who underwent cancer screenings during 2001-2011 at the National Cancer Center, Korea, were analyzed. The association between health-related behaviors and a FHCA were assessed using multivariate logistic regression.
Results
Compared to women with no FHCA, women with FHCA were more likely to smoke (adjusted odds ratio [aOR], 1.32; 95% confidence interval [CI], 1.06 to 1.65), to be exposed to passive smoking (aOR, 1.21; 95% CI, 1.15 to 1.65), and less likely to engage in regular exercise (aOR, 1.20; 95% CI, 1.01 to 1.41). Combined effects of selected health behaviors for FHCA were significant, although no statistically significant interactions were observed between selected health behaviors. Compared to women with no FHCA, women with FHCA were more likely to simultaneously smoke and be exposed to passive smoking (aOR, 1.65; 95% CI, 1.17 to 2.31) and to simultaneously smoke and be physically inactive (aOR, 1.62; 95% CI, 1.00 to 2.64).
Conclusion
The study found that women with a FHCA exhibited unhealthy behaviors compared to women without FHCA. Higher emphasis on lifestyle modifications using a new standardized tool is strongly recommended for those with a FHCA, as well as individuals who are at high risk, together with their family members.

Citations

Citations to this article as recorded by

The Effect of the Breast Cancer Risk Reduction Program on Women With High Breast Cancer Risk in Terms of Their Participation in Screening and Their Health Beliefs and Behavior
Habibe Ozcelik, Sebahat Gozum
Cancer Nursing.2024; 47(6): E376. CrossRef
The Effect of Breast Cancer Risk Reduction Program Applied to Women With High Breast Cancer Risk on Participation in Screening, Health Beliefs, and Behavior
Habibe Ozcelik, Sebahat Gozum
Cancer Nursing.2023;[Epub] CrossRef
Association between having a family member with dementia and perceptions of dementia preventability
Woojung Lee, Shelly L. Gray, Oleg Zaslavsky, Douglas Barthold, Zachary A. Marcum
Aging & Mental Health.2022; 26(2): 270. CrossRef
Genetic Liability to Smoking and Breast Cancer Risk

Zhouming Xu, Hongxia Xu, Yunlong Lu
Clinical Epidemiology.2020; Volume 12: 1145. CrossRef
Association Between Health Behaviors and Family History of Cancer According to Sex in the General Population
Minji Hwang, Hyun-Soo Zhang, Boyoung Park
American Journal of Preventive Medicine.2019; 56(3): 393. CrossRef
Association Between Health Behaviors and Family History of Cancer in Cancer Survivors: Data From the Korean Genome and Epidemiology Study
Minji Hwang, Boyoung Park
Journal of Cancer Prevention.2017; 22(3): 166. CrossRef
Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives
Simonetta Ausoni, Paolo Boscolo-Rizzo, Bhuvanesh Singh, Maria Cristina Da Mosto, Giacomo Spinato, Giancarlo Tirelli, Roberto Spinato, Giuseppe Azzarello
Cancer and Metastasis Reviews.2016; 35(3): 413. CrossRef

10,618 View
94 Download
5 Web of Science
7 Crossref

Correlation of AR, EGFR, and HER2 Expression Levels in Prostate Cancer: Immunohistochemical Analysis and Chromogenic In Situ Hybridization: Kwang Hyun Baek, Min Eui Hong, Yoon Yang Jung, Chung Hun Lee, Tae Jin Lee, Eon Sub Park, Mi Kyung Kim, Jae Hyung Yoo, Soo Whan Lee; Cancer Res Treat. 2012;44(1):50-56. Published online March 31, 2012; DOI: https://doi.org/10.4143/crt.2012.44.1.50

Abstract PDF PubReader ePub

PURPOSE
The androgen receptor (AR) plays a central role in prostate cancer. Evidence from several groups indicates that epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) may enhance AR activity in prostate cancer cell lines. This study was designed to investigate the protein expression of AR, EGFR, and HER2 and to determine whether the EGFR and HER2 genes are amplified in prostate cancer tissues.
MATERIALS AND METHODS
The protein expression levels of AR, EGFR, and HER2 in a tissue microarray block of 66 prostate cancer samples were investigated by immunohistochemical analysis and chromogenic in situ hybridization was used to determine whether the EGFR and HER2 genes were amplified in these tissues.
RESULTS
The AR and EGFR proteins were expressed in 59.1% and 40.9% of prostate cancers, respectively, but their expression levels were not significantly associated with clinicopathologic factors. Of the cases in which tissues were negative for EGFR protein expression, 69.2% were positive for AR protein expression; however, AR protein expression was significantly reduced (44.4%) in tissues in which EGFR protein was expressed. HER2 expression was detected in only 1 case (1.5%). No amplification of the EGFR or HER2 genes was found in prostate cancer specimens.
CONCLUSION
This study was limited by small number of subjects, but it can still be inferred that the expression levels of the AR and EGFR proteins are inversely correlated in prostate cancer patients. The potential utility of EGFR and HER2 as prognostic factors or therapeutic targets warrants further study.

Citations

Citations to this article as recorded by

The role of Cabazitaxel in Patients With Castration-Resistant and Osseous Metastases Prostate Cancer. A Hellenic Cooperative Oncology Group Phase II Study
Michalis Liontos, Anna Goussia, Nikolaos Korfiatis, Kyriaki Papadopoulou, Georgios Kanellis, Anastasios Visvikis, Georgios Petrakis, Marinos Tsiatas, Elena Fountzilas, Epaminontas Samantas, George Fountzilas, Eleni Efstathiou
Clinical Genitourinary Cancer.2025; 23(1): 102253. CrossRef
Revisiting HER2 in Prostate Cancer from an Inclusive Perspective: From Biomarkers to Omics
Nicole Mavingire, Janelle C. Moore, Jabril R. Johnson, Abdulrahman M. Dwead, Cheryl D. Cropp, Yehia Mechref, Firas Kobeissy, Soroush Rais-Bahrami, Leanne Woods-Burnham
Cancers.2024; 16(19): 3262. CrossRef
Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?
Sushanta Halder, Soumi Basu, Shobhit P. Lall, Apar K. Ganti, Surinder K. Batra, Parthasarathy Seshacharyulu
Expert Opinion on Therapeutic Targets.2023; 27(4-5): 305. CrossRef
The association of claudin-18 and androgen receptor expression in prostatic carcinoma: an immunohistochemical study
Heba M. Rashad, Hanan Ahmed, Kareem Ali El Attar, Eman A. Saad
Beni-Suef University Journal of Basic and Applied Sciences.2023;[Epub] CrossRef
Identification of Potential Key Genes in Prostate Cancer with Gene Expression, Pivotal Pathways and Regulatory Networks Analysis Using Integrated Bioinformatics Methods
Mohd Mabood Khan, Mohammad Taleb Mohsen, Md. Zubbair Malik, Sali Abubaker Bagabir, Mustfa F. Alkhanani, Shafiul Haque, Mohammad Serajuddin, Mausumi Bharadwaj
Genes.2022; 13(4): 655. CrossRef
FBXW2 inhibits prostate cancer proliferation and metastasis via promoting EGFR ubiquitylation and degradation
Tao Zhou, Tingting Chen, Bin Lai, Wenfeng Zhang, Xi Luo, Ding Xia, Weihua Fu, Jie Xu
Cellular and Molecular Life Sciences.2022;[Epub] CrossRef
The Potential Tumor-Suppressor DHRS7 Inversely Correlates with EGFR Expression in Prostate Cancer Cells and Tumor Samples
Simon Stücheli, Selene Araya, Caner Ercan, Seraina O. Moser, John Gallon, Paul Jenö, Salvatore Piscuoglio, Luigi Terracciano, Alex Odermatt
Cancers.2022; 14(13): 3074. CrossRef
Estrogen receptor β and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate
Wan-fu Wu, Li Wang, Nicholas Spetsieris, Myrto Boukovala, Eleni Efstathiou, Clemens Brössner, Margaret Warner, Jan-Ake Gustafsson
Proceedings of the National Academy of Sciences.2021;[Epub] CrossRef
Expression of ERBB Family Members as Predictive Markers of Prostate Cancer Progression and Mortality
Sylvie Clairefond, Véronique Ouellet, Benjamin Péant, Véronique Barrès, Pierre I. Karakiewicz, Anne-Marie Mes-Masson, Fred Saad
Cancers.2021; 13(7): 1688. CrossRef
Evaluating the effect of secretome of human amniotic mesenchymal stromal cells on apoptosis induction and epithelial‐mesenchymal transition inhibition in LNCaP prostate cancer cells based on 2D and 3D cell culture models
Fatemeh Safari, Termeh Shakery, Nadiya Sayadamin
Cell Biochemistry and Function.2021; 39(6): 813. CrossRef
The influence of testosterone suppression on HER2 immunoexpression in prostatic neoplastic tissue
Guilherme Peixoto, Fernando Korkes, Cristiano Pazeto, Marilia De Castro, Thiago Lima, Marcelo Wroclawski, Nicolle Christofe, Marcos Tobias‑Machado, Lucila Santiago, Sidney Glina
Molecular and Clinical Oncology.2021;[Epub] CrossRef
Androgen Receptor Activation in Glioblastoma Can Be Achieved by Ligand-Independent Signaling through EGFR—A Potential Therapeutic Target
Nomi Zalcman, Mijal Gutreiman, Tal Shahar, Michael Weller, Iris Lavon
International Journal of Molecular Sciences.2021; 22(20): 10954. CrossRef
Comparative expression of immunohistochemical biomarkers in cribriform and pattern 4 non-cribriform prostatic adenocarcinoma
Guang-Qian Xiao, Elise Nguyen, Pamela D. Unger, Andy E. Sherrod
Experimental and Molecular Pathology.2020; 114: 104400. CrossRef
Design and Synthesis of a Trifunctional Molecular System “Programmed” to Block Epidermal Growth Factor Receptor Tyrosine Kinase, Induce High Levels of DNA Damage, and Inhibit the DNA Repair Enzyme (Poly(ADP-ribose) Polymerase) in Prostate Cancer Cells
Julie Schmitt, Shanlong Huang, Elliot Goodfellow, Christopher Williams, Bertrand J. Jean-Claude
Journal of Medicinal Chemistry.2020; 63(11): 5752. CrossRef
EGFR/FOXO3A/LXR-α Axis Promotes Prostate Cancer Proliferation and Metastasis and Dual-Targeting LXR-α/EGFR Shows Synthetic Lethality
Tingting Chen, Jie Xu, Weihua Fu
Frontiers in Oncology.2020;[Epub] CrossRef
KRAS, BRAF, PIK3CA mutation frequency of radical prostatectomy samples and review of the literature
Atike Bahcivan, Mehmet Gamsizkan, Sinem Kantarcioglu Coskun, Sengul Cangur, Alpaslan Yuksel, Aysegul Ceyhan, Binnur Onal
The Aging Male.2020; 23(5): 1627. CrossRef
Identification of Potential miRNAs Biomarkers for High-Grade Prostate Cancer by Integrated Bioinformatics Analysis
Laura Foj, Xavier Filella
Pathology & Oncology Research.2019; 25(4): 1445. CrossRef
Prognostic utility of epidermal growth factor receptor (EGFR) expression in prostatic acinar adenocarcinoma
Atif Ali hashmi, Shumaila Kanwal Hashmi, Muhammad Irfan, Huda Asif, Laila Nisar, Maheen Naeem, Erum Yousuf Khan, Samina Baloch, Naveen Faridi
Applied Cancer Research.2019;[Epub] CrossRef
3D porous chitosan-alginate scaffold stiffness promotes differential responses in prostate cancer cell lines
Kailei Xu, Kavya Ganapathy, Thomas Andl, Zi Wang, John A. Copland, Ratna Chakrabarti, Stephen J. Florczyk
Biomaterials.2019; 217: 119311. CrossRef
Correlation of Gleason Grading and Prognostic Immunohistochemistry Markers (Human Epidermal Growth Factor Receptor 2/neu and Androgen Receptor) in Prostatic Core Needle Biopsy: A Study in a Tertiary Care Center
Utsha Senapati, Moumita Sengupta, Chhanda Datta, Uttara Chatterjee, Dilip Kumar Pal, Diya Das, Piyali Poddar
Indian Journal of Medical and Paediatric Oncology.2019; 40(02): 201. CrossRef
Dysregulated gene expression predicts tumor aggressiveness in African-American prostate cancer patients
Hamdy E. A. Ali, Pei-Yau Lung, Andrew B. Sholl, Shaimaa A. Gad, Juan J. Bustamante, Hamed I. Ali, Johng S. Rhim, Gagan Deep, Jinfeng Zhang, Zakaria Y. Abd Elmageed
Scientific Reports.2018;[Epub] CrossRef
Individualization of Adjuvant Therapy After Radical Prostatectomy for Clinically Localized Prostate Cancer: Current Status and Future Directions
Darrion L. Mitchell, Chad R. Tracy, John M. Buatti, Mark C. Smith, Anthony N. Snow, Michael D. Henry, Daniel A. Vaena, Hamed H. Tewfik, John M. Watkins
Clinical Genitourinary Cancer.2016; 14(1): 12. CrossRef
Antitumoral action of icaritin in LNCaP prostate cancer cells by regulating PEA3/HER2/AR signaling
Jimeng Hu, Wenhui Zhu, Bingbing Wei, Hui Wen, Shanhua Mao, Hua Xu, Mengbo Hu, Tian Yang, Haowen Jiang
Anti-Cancer Drugs.2016; 27(10): 944. CrossRef
Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy
Takatsugu Okegawa, Naoshi Itaya, Hidehiko Hara, Mitsuhiro Tambo, Kikuo Nutahara
International Journal of Molecular Sciences.2016; 17(12): 2008. CrossRef
Epidermal Growth Factor Receptor in Prostate Cancer Derived Exosomes
Geetanjali Kharmate, Elham Hosseini-Beheshti, Josselin Caradec, Mei Yieng Chin, Emma S. Tomlinson Guns, Daotai Nie
PLOS ONE.2016; 11(5): e0154967. CrossRef
HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method
Nazanin Sharifi, Arash Salmaninejad, Samira Ferdosi, Abolfazl Nesaei Bajestani, Malihe Khaleghiyan, Mehrdad Asghari Estiar, Mansour Jamali, Mohammad Reza Nowroozi, Abbas Shakoori
Oncology Letters.2016; 12(6): 4651. CrossRef
Imaging of HER2 may improve the outcome of external irradiation therapy for prostate cancer patients
JENNIE ANDERSSON, MARIA ROSESTEDT, ANNA ORLOVA
Oncology Letters.2015; 9(2): 950. CrossRef
NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer
Chuigong Yu, Guojun Wu, Ruixiao Li, Lei Gao, Fan Yang, Yi Zhao, Jian Zhang, Rui Zhang, Jing Zhang, Libo Yao, Jianlin Yuan, Xia Li
Cancer Biology & Therapy.2015; 16(2): 287. CrossRef
MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance
Richard Ottman, Camha Nguyen, Robert Lorch, Ratna Chakrabarti
Molecular Cancer.2014;[Epub] CrossRef
Overexpression of HER-2/neu in Patients with Prostatic Adenocarcinoma
Shokouh Taghipour Zahir, Hamid Fallah Tafti, Koorosh Rahmani
Asian Pacific Journal of Cancer Prevention.2014; 15(15): 6425. CrossRef
ERG Rearrangement Is Associated with Prostate Cancer-Related Death in Chinese Prostate Cancer Patients
Mei Qi, Xiaoqing Yang, Fan Zhang, Tao Lin, Xiubin Sun, Yanjiang Li, Huiqing Yuan, Yubo Ren, Juan Zhang, Xiaomin Qin, Bo Han, Jindan Yu
PLoS ONE.2014; 9(2): e84959. CrossRef
In vitro modeling of HER2-targeting therapy in disseminated prostate cancer
JENNIE ANDERSSON, MARIA ROSESTEDT, VERONIKA ASPLUND, NAZILA YAVARI, ANNA ORLOVA
International Journal of Oncology.2014; 45(5): 2153. CrossRef
Cell mates: paracrine and stromal targets for prostate cancer therapy
Pavel Sluka, Ian D. Davis
Nature Reviews Urology.2013; 10(8): 441. CrossRef
Bioinformatic Analysis of the Canine Genes Related to Phenotypes for the Working Dogs
Yun-Jeong Kwon, Jungwoo Eo, Bong-Hwan Choi, Yuri Choi, Jeong-An Gim, Dahee Kim, Tae-Hun Kim, Hwan-Hoo Seong, Heui-Soo Kim
Journal of Life Science.2013; 23(11): 1325. CrossRef

59,568 View
125 Download
34 Crossref

A Phase II Study of Weekly Paclitaxel, Cisplatin and Concurrent Radiation Therapy for Locally-Advanced Unresectable Non-Small Cell Lung Cancer: Early Closure due to Lack of Efficacy: Se Hoon Park, Mi Kyung Kim, Sun Young Kyung, Young-Hee Lim, Chang Hyeok An, Jeong Woong Park, Seong Hwan Jeong, Jae Woong Lee, Kyu Chan Lee, Eun Kyung Cho, Soo Mee Bang, Dong Bok Shin, Jae Hoon Lee; Cancer Res Treat. 2004;36(5):293-297. Published online October 31, 2004; DOI: https://doi.org/10.4143/crt.2004.36.5.293

Abstract PDF PubReader ePub: Purpose
In this phase II study, the efficacy and safety of weekly paclitaxel concomitant with cisplatin and thoracic radiotherapy (TRT) was evaluated in patients with locally-advanced unresectable non-small cell lung cancer (NSCLC).
Materials and Methods
Patients with stage III NSCLC (without pleural effusion or cervical lymphadenopathy) received TRT (63 Gy in 35 fractions over 7 weeks) with concurrent weekly cisplatin 20 mg/m² and paclitaxel 40 mg/m²/week infused over 3 hours. In patients without evidence of disease progression, the administration of a further 2 cycles of consolidation chemotherapy, consisting of paclitaxel 175 mg/m² and cisplatin 75 mg/m², were planned after completion of the TRT.
Results
Between Feb 2000 and Dec 2002, 20 patients were entered into the study; 13 completed all 7 weeks of treatment (median 7.6 weeks; range 3.3 to 9.4). Seven out of 16 (43.8%) objective responses were observed, with 15 (75%) patients experiencing at least one episode of grade 3/4 toxicity. The main toxicities were moderate to severe neutropenia and gastrointestinal toxicity.
Conclusion
The unsatisfactory response rate and the high incidence of grade 3/4 hematologic and non-hematologic toxicities, including 7 early discontinuations of treatment and exceeding the study stopping rules, prompted the early closure of the study. In view of the activity observed, the protocol was amended to protracted continuous infusion paclitaxel, cisplatin and concurrent TRT.

8,556 View
53 Download

Proteomic Profiling of Human Small Cell Lung Cancer Cell Line NCI-H211: Hee Young Cho, Mi Kyung Kim, Young Do Yoo, Myung Ju Ahn, Joung Soon Jang; Cancer Res Treat. 2003;35(6):489-496. Published online December 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.6.489

Abstract PDF: PURPOSE
Small cell lung cancer is one of the major causes of death from cancer worldwide. To explore the expressions of global protein in small cell lung cancer cells, a proteomic approach, to identify the proteins, was used and the establishment of a protein reference map attempted.
MATERIALS AND METHODS
Two-dimensional gel electrophoresis (2-DE), with subsequent analysis by mass spectrometry (MS), was applied to the study of protein identification from a small cell lung cancer cell line, NCI- H211. The cells were lysed, and the extracts subjected to isoelectric focusing, with immobilized pH gradients, followed by second dimension SDS-PAGE. The polypeptides were identified by peptide mass fingerprinting, with MALDI-TOF MS, after in-gel protein digestion. RESULTS: From silver staining of the gel, around two thousands protein spots were separated by the 2-DE. Of these protein spots visualized in the gel, one hundred and ten were identified by peptide mass fingerprinting. Different proteins, such as enzymes, cytoskeletal proteins and proteins common to eukaryotic cells, were identified.
CONCLUSION
The protein expressions of the small cell lung cancer cells were analyzed to establish a protein reference map. The reference map presented here may serve as a working tool for the further study of small cell lung cancer.

4,292 View
50 Download

Effect of p53 and p16 Protein Expression in Relation to Body Mass Index for Breast Cancer Risk: Mi Kyung Kim, Jung Yeon Kim, Gyung yub Gong, Sei Hyun Ahn; J Korean Cancer Assoc. 2001;33(2):149-157.

Abstract PDF: PURPOSE
This study was conducted to investigate whether breast cancer with p53 protein overexpression (p53+) and loss of p16 protein expression (p16-) shows different body size indicator (height, weight, body mass index) associations as compared with breast tumors without p53 protein overexpression and the loss of p16 expression (p53-, p16+).
MATERIALS AND METHODS
A hospital based case-control study was conducted among 92 women patients and 122 control subjects. The p53 protein overexpression and loss of p16 protein expression in the tissue sections of patients with breast cancer were determined using immunohistochemistry.
RESULTS
A total of 26 tumors (28%) demonstrated p53 overexpression and 35 tumors (46%) showed abnormal p16 expression. The heaviest women had a higher risk with p53- and p16+ breast tumors. The odds ratios (OR) adjusted for age, menopausal status, smoking, and drinking revealed a significant gradient of increasing risk of breast cancer with increasing BMI in p53- and p16+ breast cancer. The adjusted ORs for the highest quintile of BMI was 8.51 with p53+ tumors and 14.2 with p53- tumors, and 55.6 with p16+ tumors and 3.72 with p16- tumors. p53 protein overexpression and the loss of p16 expression did not significantly correlate with nodal status, tumor size, estrogen or progesterone receptor status.
CONCLUSION
The study concluded that a strong association between p53-/p16+ tumors and BMI suggests the occurrence of p53-/p16+ tumors is related with obesity as compared to p53-/p16+ tumors.

3,351 View
28 Download

Relation between Body Size and Body Mass Index and Breast Cancer by Menopausal Status in Korea: Se Hyun Ahn, Mi Kyung Kim, Suk Il Kim; J Korean Cancer Assoc. 1999;31(1):72-81.

Abstract PDF: PURPOSE
Because the breast cancer is one of the major causes of mortality among women, it is important to identify modifiable risk factors for this disease. Some reported that overweight/obesity is a risk factor for breast cancer, but the results are not consistent. Human breast cancer has different characteristics according to the status of menopause (premenopause and postmenopause). For the premenopaused women, the majority of the relevant prospective studies support an inverse relationship between body mass index and the development of breast cancer. In contrast, for the postmenopaused women, a positive relationship between body mass index and development of breast cancer has been reported in only half of prospective studies on this topic. This study was undertaken to determine the role of body size and body mass index by status of menopause in development of breast cancer in Korea using retrospective case-control study.
MATERIALS AND METHODS
The breast cancer cases (n=683) and controls (n=501) were recruited from January 1993 to April 1998 at the Asan Medical Center. The authors collected information on demographic, reproductive and anthropometric characteristics by interviews. Quetelets index was calculated using height and weight. Multiple logistic regression was done to estimate adjusted odds ratios (ORs) by menopausal status, controlling age, age at first full-tenn pregnancy, age at menarche, number of parity, family history of breast cancer.
RESULTS
Overall, there was a moderate, but significant association between obesity and breast cancer. Among premenopausal women, in comparison with women whose weights were less than 50 kg, the ORs for the upper quintile group of weight was 1.71 (95% confidence interval (CI), 1.01~2.89). The heaviest premenopausal women had a higher risk (OR=1.16, 95% CI, 1.05~1.29, P=0.005). The adjusted OR for the highest quintile of BMI relative to the lowest was 2.02 (95% CI, 1.18~3.45). Higher body mass index was significantly associated with increased risk of premenopausal breast cancer (OR=1.08, 95% CI, 1.02~1.15, P=0.006). Among postmenopausal women, higher body mass index and weight were associated with increased risk of breast cancer. In comparison with women whose weights were less than 50 kg, the OR for the upper quintile group of weight was 2.08 (95% CI, 1.064.08). The adjusted OR for the highest quintile of BMI relative to the lowest was 2.02 (95% CI, 1.02~4.01).
CONCLUSION
Our findings suggest that overweight/obesity may play an important role in the incidence of premenopausal and postmenopausal breast cancer in Korea.

2,802 View
20 Download

Expression of p53 and MHC Class I According to HPV Infection in Laryngeal Squamous Cell Carcinomas: Chan Seung Hwang, Hoon Kim, Mi Kyung Kim; J Korean Cancer Assoc. 1998;30(1):1-11.

Abstract PDF: PURPOSE
We evaluated the HPV type 16, 18 infection and p53 expression and MHC class Iantigen expression, and analyzed he relationship between HPV infection and p53 expression and MHC class I expression in laryngeal squamous cell carcinomas.
MATERIALS AND METHODS
Thirty-nine cases of laryngeal squamous cell carcinomas and ten cases of laryngeal nodules were analyzed for detection of HPV DNA by in situ hybridization and the detection of p53 and MHC class I antigen by immunohistochemical technique.
RESULTS
HPV DNA was detected in 10(26%), and p53 expression was detected in 19(49%) out of 39 cases in laryngeal squamous cell carcinomas. HPV positive cases showed 50% of p53 expression whereas HPV negative cases showed 48% expression. MHC class I down-regulation (heterogenous and negative expression) in HPV positive lesions was higher than HPV negative lesions, but there was no statistically significance. The expression of MHC class I was related to cellular differentiation regardless of T-stage and nodal involvement.
CONCLUSION
There was no reiationship between HPV infection and p53 expression and MHC class I expression in laryngeal squamous cell carcinomas. Also these results suggest that MHC class I expression can make it possible to presume indirectly the malignant potentiality of the tumor.

2,578 View
12 Download

Immunohistochemical and Genetic Changes in Putative Preneoplastic Lesion in Rat Liver: Kye Yong Song, Dae Young Kim, Hyung Chun Kim, Mi Kyung Kim, Young Ho Rha, Sang Chul Park; J Korean Cancer Assoc. 1990;22(3):395-410.

Abstract PDF: Immunohistochemical and electron microscopic studies were carried out on the preneoplastic nodule, to observe the morphological and immunohistochemical changes of the transformed preneo- plastic hepatacytes by immunohistochemical method using antibodies to the various marker enzymes such as glutathione S-transferase of placental form (GST-P), glutathione S-transferase of basic form (GST-L), Glucose 6 phosphate dehydrogenase (G6PDH), gamma glutamyl transpeptidase (GGT) The results obtained were as follaws; l) The transformed preneoplastic hepatocytes could be detected easily by use af GST-P antibody especially in the clear cell nodule from the 2nd month and is significantly increased from the 12th month compar'ed with the 2nd month, while basophilic nodule was observed from the 10th month. 2) Immunohistochemical staining revealed strong positive reaction to GST-P and weakly positive to G6PDB, GST-L and focally poitive to GGT in clear cells, while weak or negative reaction to GST-P, G6PDH, GST-L and GGT in eosinophilic cells. and Basophilic cells showed negative reaction to GST-P, GST-P, GST-L, G6PDH and positive to GGT. 3) Electron microscopically, clear cells revealed abundant glycogen particles and well developed endoplasmic reticulum, while eosinophilic cell reveaied abundant mitochondria and vacuoles with a few glycogen, basophilic cells revealed abundant rER and ribosomes. Immunohistochemically, GST-P is abundantly distributed in the cytoplasm especially around the rER, vesicles and alsp in nucleus. 4) Therefore, glutathione S-transferase is a good marker for early detection of genetically transformed and preneoplastic hepatacytes especially clear cell while GGT is positive marker for basophilic cell. GST-P is abundantly present in the cytosol and around the rER and vesicle. The clearness of preneoplastic hepat.ocytes were thought as the result of marked increase of glycogen while basophilic cells were the result of marked incresed rER.

2,604 View
17 Download

Immunohistochemical Analysis of Transforming Growth Factor - β Isoforms ( TGF-β1 , TGF-β2 , TGF-β3 ) Expression in Gastric Adenocarcinoma: Jae Hyung Yoo, Weon Sub Park, Mi Kyung Kim, Tae Jin Lee, Sang Jun Lee; J Korean Cancer Assoc. 1996;28(6):1040-1050.

Abstract PDF: Immunohistochemical studies using polyclonal antibodies to transforming growth factor beta isoforms(TGF-￥a1, TGF-￥a2 & TGF-￥a3), a multifunctional regulatory proteins which hoave effects on normal and transformed cells, were performed on 66 cases of gastric adenocarcinomas in order to analyze the relationship between expression of these isoforms in gastric cancer cells, adjacent mucosa of the cancer and normal control gastric mucosa. In addition to determine the relationship between expression of TGF-￥a isoforms and various clinicopathological states, including tumor location, histologic types, regional lymph node metastasis and depth of invasion of tumors were carried out. The positive staining reactivity was detected within the cytoplasm and on the cell membrane. The rate of TGF-￥a isoforms expression in gastric adenocarcinomas were 47% in TGF-￥a1, 83% in TGF-￥a2, and 27% in TGF-3, respectively. The adjacent gastric mucosa from adenocarcinomas and normal control mucosa were 40 % in TGF-￥a1, 40% and 55% in TGF-￥a2, 20% and 33% in TGF-￥a3, respectively. Among the TGF-￥a isoforms, TGF-￥a2 was strongly associated with histologic differentiation and regional lymph node metastasis. No significant association was found between expression of TGF-￥a isoforms and tumor location, histologic types and T-stages. From these results, we can postulate that the altered expression of TGF-￥a isoforms, especially TGF-￥a2, play an important role in histogenesis and gastric cancer progression and regional lymph node metastasis.

2,729 View
12 Download

First
Prev
Page of 1
Next
Last

Search